doctrine of obviousness-type double patenting

Following a four-day bench trial before him in Shire Orphan Therapies LLC et al. v. Fresenius Kabi USA, LLC, Civil Action No. 15-1102-GMS (D.Del. June 5, 2018), and having considered the entire record in the case and the applicable law, The Honorable Gregory M. Sleet issued the Court’s Memorandum setting forth the findings of fact

By Memorandum Opinion entered by The Honorable Sue L. Robinson in Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc., Civil Action No. 14-874-SLR (D.Del., November 16, 2016), the Court found the asserted claims of U.S. Patent No. 6,127,353 (“the ‘353 patent”) are valid but that defendant does not infringe the asserted claims

By Memorandum Opinion entered by Chief Judge Gregory M. Sleet, following a five-day bench trial, in Eli Lilly and Company, et al. v. Teva Parenteral Medicines, Inc., et al., Civil Action No. 08-335-GMS (D.Del., July 28, 2011), the Court set forth its findings of fact and conclusions of law and entered judgment in